SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial
TipRanks (Tue, 7-Jul 8:49 AM ET)
Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes
Globe Newswire (Tue, 7-Jul 8:00 AM ET)
Globe Newswire (Fri, 29-May 8:00 AM ET)
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
Globe Newswire (Tue, 12-May 7:30 AM ET)
Globe Newswire (Tue, 5-May 8:30 AM ET)
Globe Newswire (Wed, 29-Apr 7:35 AM ET)
Globe Newswire (Wed, 22-Apr 7:00 AM ET)
Globe Newswire (Wed, 15-Apr 8:00 AM ET)
SAB BIO Closes $85 Million Public Offering to Propel Development of T1D Therapy
Market Chameleon (Fri, 20-Mar 7:26 AM ET)
Market Chameleon (Wed, 11-Mar 6:34 AM ET)
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Sab Biotherapeutics trades on the NASDAQ stock market under the symbol SABS.
As of July 8, 2026, SABS stock price declined to $3.77 with 1,045,319 million shares trading.
SABS has a beta of 0.57, meaning it tends to be less sensitive to market movements. SABS has a correlation of 0.01 to the broad based SPY ETF.
SABS has a market cap of $288.27 million. This is considered a Small Cap stock.
In the last 3 years, SABS traded as high as $10.50 and as low as $1.00.
The top ETF exchange traded funds that SABS belongs to (by Net Assets): VTI, IWM, IWN, VXF, IWC.
SABS has outperformed the market in the last year with a return of +92.3%, while the SPY ETF gained +21.3%. However, in the most recent history, SABS shares have underperformed the stock market with its stock returning +0.3% in the last 3 month period and -2.6% for the last 2 week period, while SPY has returned +13.4% and +1.6%, respectively.
SABS support price is $3.72 and resistance is $4.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SABS shares will trade within this expected range on the day.